This study investigates relationship between fatty liver prognosis and body composition analysis result based on non-contrast low dose CT in patients with fatty liver disease.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
150
target effective dose: \< 1.5 mSv It is performed twice in 6-month interval.
Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis.
BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used.
Seoul National University Hospital
Seoul, South Korea
relationship between body composition analysis result from CT and liver fat fraction
relationship between visceral fat volume fraction (obtained from CT analysis using automatic body segmentation, unitless (visceral fat fraction = visceral fat volume/total body volume)) and CAP value of fibroscan
Time frame: 6 month after CT acquisition
ratio of appropriate non-contrast low dose abdomen CT acquisition & analysis
Number of CT scan with effective dose \< 1.5 mSv AND successful automatic body composition analysis (without manual editing) divided by total number of CT scan
Time frame: 6 month after CT acquisition
relationship between body composition analysis result from CT and hepatic fibrosis
relationship between visceral fat volume fraction (CT analysis using automatic body segmentation, unitless (visceral fat fraction = visceral fat volume/total body volume)) and liver stiffness value of fibroscan
Time frame: 6 month after CT acquisition
agreement between body composition analysis result from CT and bioelectrical impedance analysis (Inbody test)
agreement of visceral fat, subcutaneous fat, muscle amount between CT based body composition and Inbody test results
Time frame: 6 month after CT acquisition
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.